did you Received this e-mail today?-Just an UPDATE: IMMC-OTCBB: Immunis Corp.- Shareholder Update:
A number of investment analysts and medical research organization's believe that Biotech Ltd.'s DIAB-II drug will be the leading treatment for Type-II diabetes in Brazil. An unconfirmed report revealed that Brazilian's socialized medical administrators (Brazil's
FDA) did not approve Rezulin as a treatment for Type-II. The controversial Rezulin produced and distributed from Warner-Lambert (WLA-NYSE) is believed to cause numerous complications and deaths.
Clinical trials from Biotech's Brazilian partner Biobras S.A. is entering its FINAL 2-3 weeks. The preliminary information thus far shows extraordinarily positive results. Biobras S.A. maintains accurate documentation which verifies the same overwhelming
results that CHINA found prior to DIAB-II approval . Upon successful completion, the Brazilian socialized medical administrators should allow DIAB-II to be sold and distributed throughout the country.
In recent days, IMMC continues to be inundated with calls from many world wide health organization, medical journals, medical reporters, and North American diabetic associations about DIAB-II's efforts in Latin America. Apparently, the seriousness of Type-II and its immediate treatment continues to be recognized throughout the world.
Many see Biotech's DIAB-II to be a cost-effective and healthier treatment of Type-II. DIAB-II drug and treatments continue to show NO major side effects. Other treatments usually cause liver, kidney and obesity side effects.
IMMC receives a 25% payment for all sales and distributions on DIAB-II outside of CHINA per its legal agreement with Biotech Ltd. IMMC new release, April 15, 1999 pointed out that a sizable and lucrative market for DIAB-II exist in Latin America. For each 1% of the diabetic population in Brazil and Argentina, DIAB-II sales would be
around $20,000,000 of which IMMC would receive 25%. Many investment analysts recognize the pharmaceutical sector at a true bargain in terms of current valuations. Immunis continues to be a shareholder favorite with NO Debt, nominal overhead, and very tight stock structure. This appeals to SMART growth stock investors!! |
